Study guide
Blood pressure and cardiovascular risk
AMC CAT MCQ Examination AMC Part 1
Track your progress as you read
Finished sections get a check mark.
1 Acute Coronary Syndromes & ECG Localization
ACS recognition and ECG localisation Reperfusion and infarction complications
2 Heart Failure, Cardiogenic Shock & Cardiac Arrhythmias
Heart failure assessment and treatment Arrhythmias and conduction emergencies
3 Systemic Hypertension & Peripheral Vascular Disease
Blood pressure and cardiovascular risk Secondary hypertension and arterial disease
4 Valvular Heart Disease, Infective Endocarditis & Pericarditis
Aortic and mitral valve disease Endocarditis and pericardial emergencies
5 Asthma & COPD Acute Flares and Maintenance
Asthma and COPD diagnosis and maintenance Acute asthma and COPD exacerbations
6 Pneumonia, pleural disease and respiratory failure
Pneumonia and infected pleural collections Pulmonary embolism, effusions and pneumothorax Respiratory failure, ARDS and sepsis
7 GI bleeding, bowel inflammation and malabsorption
GI bleeding assessment and resuscitation Varices, ulcers, reflux and lower GI bleeding IBD patterns and severe colitis assessment IBD treatment, coeliac disease and IBS
8 Chronic Liver Disease, Cirrhosis Complications & Acute Hepatitis
Cirrhosis diagnosis and prognosis Decompensation, viral hepatitis and surveillance
9 Diabetes, thyroid and adrenal disease
Diabetes diagnosis and ongoing care DKA, HHS and complication monitoring Thyroid disease assessment Thyroid emergencies and adrenal disease
10 Acute Kidney Injury, Chronic Kidney Disease & Fluid/Electrolyte Emergencies
AKI and chronic kidney disease Potassium and sodium emergencies
11 Anaemias, Inflammatory Arthropathies & Geriatric Comprehensive Assessment
Anaemia, bruising and blood disorders Arthritis, autoimmune disease and geriatric care
12 Evaluation of the Acute Abdomen, Peritonitis & Appendicitis
Abdominal pain, peritonitis and resuscitation Appendicitis diagnosis and treatment Perforation and mesenteric ischaemia
13 Small and Large Bowel Obstruction & Colorectal Surgical Pathology
Small bowel obstruction Colonic obstruction, volvulus and cancer recognition Colorectal care, diverticulitis and anorectal symptoms
14 Gallbladder Disease, Biliary Tract Infections & Acute Pancreatitis
Gallstones and biliary obstruction Cholangitis and pancreatitis diagnosis Pancreatitis severity and treatment
15 Advanced Trauma Life Support, Primary Survey & Life-Threatening Thoracic Injuries
Trauma primary survey and adjuncts Chest trauma and immediate threats
16 Traumatic Brain Injury, Intracranial Haemorrhage & Spinal Cord Clearance
Head injury, imaging and haemorrhage Herniation and spinal cord injury
17 Major Fractures, Joint Dislocations & Acute Compartment Syndrome
Fracture assessment and open injuries Compartment syndrome, dislocations and pelvic injury
18 Thermal Burns, Haemorrhagic Shock Resuscitation & Surgical Wound Care
Burn assessment and fluid resuscitation Bleeding shock, wound care and tetanus
19 Aortic Aneurysms & Acute Arterial Limb Ischaemia
Aneurysm recognition and planned care Ruptured aneurysm and acute limb ischaemia
20 Urological Emergencies, Testicular Torsion & Haematuria Investigation
Retention, stones and obstructed infection Scrotal pain and haematuria
21 Preoperative Risk Stratification & Postoperative Surgical Complications
Preoperative assessment and medicines Postoperative complications and prevention
22 Early Pregnancy Bleeding, Ectopic Pregnancy & Antenatal Screening
Miscarriage and ectopic pregnancy Antenatal screening and early-pregnancy comparisons
23 Hypertensive Disorders of Pregnancy & Medical Complications in Pregnancy
Pregnancy hypertension and preeclampsia Eclampsia, HELLP and antepartum bleeding
24 Intrapartum Monitoring, Postpartum Haemorrhage & Obstetric Emergencies
Labour physiology and CTG assessment CTG response and postpartum haemorrhage Obstetric emergencies and preterm birth
25 Abnormal Uterine Bleeding, Pelvic Pain & Endometriosis
Abnormal bleeding and structural causes Endometrial sampling and endometriosis PCOS diagnosis and long-term care
26 Contraception, Emergency Contraception & Pregnancy Termination
Contraceptive choice and missed pills Emergency contraception and abortion
27 Australian Cervical Screening Program & Gynaecological Malignancies
Cervical screening and cervical cancer Endometrial and ovarian cancer
28 Neonatal Resuscitation, Congenital Conditions & Neonatal Jaundice
Newborn resuscitation, Apgar and cyanosis Neonatal jaundice assessment Jaundice treatment and congenital screening
29 Developmental Milestones, Growth Charts & Failure to Thrive
Developmental milestones Regression, autism and support Faltering growth and developmental comparisons
30 The Limping Child, Septic Arthritis vs Transient Synovitis & Paediatric Hip Conditions
Limp assessment and septic-joint risk Joint-infection management and Perthes disease SUFE and paediatric hip comparisons
31 Croup, Bronchiolitis, Paediatric Asthma & Anaphylaxis
Croup Bronchiolitis Paediatric asthma Paediatric anaphylaxis
32 Evaluation of the Febrile Child, Sepsis & Meningococcal Disease
Febrile neonates and young infants Meningococcal disease and paediatric sepsis Bacterial meningitis and CSF interpretation Kawasaki disease and follow-up
33 Paediatric Surgical Abdomen, Dehydration & Child Protection / Non-Accidental Injury
Pyloric stenosis Intussusception and dehydration Child protection and injury assessment
34 The Mental State Examination & Suicide Risk Stratification
Mental state examination and psychotic symptoms Suicide formulation and mental health law
35 Major Depressive Disorder, Bipolar Affective Disorder & Mood Stabilisers
Depression assessment and treatment Serotonin toxicity and bipolar presentations Mood stabilisers and ECT
36 Generalised Anxiety, Panic Disorder, PTSD & Obsessive-Compulsive Disorder
Anxiety, panic and agoraphobia OCD and trauma-related disorders
37 Schizophrenia, Acute Psychosis & Antipsychotic Management
Psychosis assessment and antipsychotics Clozapine and severe adverse effects
38 Substance Use Disorders & Acute Withdrawal Syndromes
Substance disorders and alcohol withdrawal Wernicke disease, opioids and stimulants
39 Delirium vs Dementia, Perinatal Mood Disorders & Paediatric Psychiatry
Delirium and dementia assessment Cognitive behaviour, perinatal and childhood psychiatry
40 Medicare, PBS, AHPRA & Good Medical Practice Framework
Australian health services and Medicare PBS access and professional registration Professional boundaries and notifications
41 Informed Consent (Rogers v Whitaker), Mental Capacity & Involuntary Treatment
Consent, material risks and young people Capacity, refusal and substitute decisions
42 Patient Privacy, Confidentiality Exceptions & Mandatory Notifications
Privacy, disclosure and child reporting Driving fitness and threat disclosure
43 First Nations health and preventive care
First Nations health, determinants and cultural safety Community care, Item 715 and CTG medicines Immunisation and cancer screening entry points Screening pathways and primary CVD prevention
44 Epidemiological Metrics, Clinical Study Designs & Notifiable Communicable Diseases
Epidemiology, calculations, bias and surveillance
45 Neurological presentations
Stroke, TIA and focal weakness Headache, facial pain and vertigo Seizures, collapse and altered consciousness Numbness, movement disorders and generalised weakness
46 Musculoskeletal pain
Back, neck, bone and soft tissue pain
47 Eye presentations
Altered vision and retinal disease Red eye, ocular injury and discharge
48 Ear, nose, throat and oral health
Ear pain, hearing loss and tinnitus Nasal problems, neck lumps, hoarseness and dysphagia Toothache, mouth symptoms, dry mouth and halitosis
49 Skin, hair and nails
Rash, itch, infection and skin ulcers Skin lesions, hair loss and nail abnormalities
50 Breast health and feeding
Breast lumps, discharge and breastfeeding problems
51 Sexual and reproductive presentations
Genital symptoms, discharge and pelvic infection Menopause, prolapse and urinary symptoms Infertility and sexual dysfunction
52 Palliative care and carers
The dying patient, symptoms and carers
53 Eating disorders and personality care
Eating disorders, obesity and weight change Personality difficulties, self-harm and complex care
54 Sleep presentations
Insomnia, snoring and daytime sleepiness
55 Poisoning, resuscitation and environmental emergencies
Poisoning, toxidromes and antidote decisions Cardiopulmonary arrest, choking and emergency help Bites, stings, heat, cold and drowning
56 Communication, rights and professional practice
Communication, handover, errors and complaints Healthcare rights, inclusive care and equitable access Certificates, deaths, CPD and supervision Telehealth, images, prescribing and doctors' health
57 Genetics, research and donation
Genetic testing, research and organ donation
58 Travel, fever and outbreaks
Fever, travellers and outbreak response
Blood pressure and cardiovascular risk
Key Takeaways Explain This Topic AI
Five-year Australian CVD risk is low below 5%, intermediate from 5 to below 10%, and high from 10%.
Established CVD requires secondary prevention rather than primary-risk calculation.
Lifestyle and medicine decisions should consider absolute risk and patient preferences.
Last updated: October 2026
Systemic Hypertension & Peripheral Vascular Disease
Systemic hypertension is the single greatest modifiable risk factor for cardiovascular disease, stroke, chronic kidney disease, and vascular dementia in Australia. Modern clinical practice shifts the therapeutic focus from isolated blood pressure thresholds to comprehensive absolute cardiovascular disease (CVD) risk assessment , ensuring that lifestyle interventions and pharmacotherapy are targeted according to overall vascular risk.
Diagnostic Criteria and Blood Pressure Measurement Modalities
Accurate measurement of blood pressure is essential to avoid misclassification:
In-Clinic Measurement : The patient should be seated quietly in a chair with back supported for at least 5 minutes prior to measurement, feet flat on the floor, and the arm supported at heart level. An appropriately sized cuff must be used (bladder encircling 80 % to 100 % 80\%\text{ to }100\% 80% to 100% of the arm circumference). A diagnosis of hypertension requires a clinic systolic blood pressure (SBP) ≥ 140 mmHg \ge 140\text{ mmHg} ≥ 140 mmHg and/or diastolic blood pressure (DBP) ≥ 90 mmHg \ge 90\text{ mmHg} ≥ 90 mmHg confirmed across at least two separate clinical consultations, unless the baseline reading is severely elevated ( ≥ 180 / 110 mmHg \ge 180/110\text{ mmHg} ≥ 180/110 mmHg ) or accompanied by acute target organ damage.
Ambulatory Blood Pressure Monitoring (ABPM) : Recognized as the reference standard out-of-office modality. Confirms hypertension if the 24-hour mean is ≥ 130 / 80 mmHg \ge 130/80\text{ mmHg} ≥ 130/80 mmHg , the daytime (awake) mean is ≥ 135 / 85 mmHg \ge 135/85\text{ mmHg} ≥ 135/85 mmHg , or the nighttime (asleep) mean is ≥ 120 / 70 mmHg \ge 120/70\text{ mmHg} ≥ 120/70 mmHg . ABPM also identifies abnormal nocturnal non-dipping patterns (failure of SBP to fall by > 10 % > 10\% > 10% at night), which is a powerful independent predictor of adverse cardiovascular and cerebrovascular outcomes.
Home Blood Pressure Monitoring (HBPM) : Recommended for confirming the diagnosis and long-term surveillance. The patient performs duplicate morning and evening measurements for 7 consecutive days. Day 1 measurements are discarded, and the mean of the remaining readings is calculated. A home average ≥ 135 / 85 mmHg \ge 135/85\text{ mmHg} ≥ 135/85 mmHg confirms hypertension.
Phenotypic Discrepancies :
White-Coat Hypertension : Elevated in-clinic blood pressure with normal ABPM/HBPM readings. Carries modest long-term risk; managed with lifestyle modification and annual surveillance.
Masked Hypertension : Normal clinic blood pressure with elevated out-of-office ABPM/HBPM readings. Carries a cardiovascular risk equivalent to sustained hypertension and requires formal antihypertensive drug therapy.
Australian Absolute Cardiovascular Disease Risk Assessment (2023+ Guidelines)
In 2023, the Australian Cardiovascular Health and Prevention Alliance and the National Heart Foundation released the updated Australian Guideline for assessing and managing cardiovascular disease risk . This replaced the older Framingham-based risk charts with a modern Australian algorithm derived from the New Zealand PREDICT cohort, recalibrated for contemporary Australian population incidence:
Target Screening Populations
All asymptomatic individuals aged 45 to 79 years without pre-existing CVD.
All First Nations (Aboriginal and Torres Strait Islander) peoples aged 30 to 79 years , reflecting earlier onset of vascular disease and health inequities.
People with diabetes aged 35 to 79 years .
Stratification Categories (5-Year Risk of a Cardiovascular Event)
Low Absolute Risk ( < 5 % < 5\% < 5% ) : Managed with lifestyle interventions (dietary modification, physical activity, alcohol limitation, smoking cessation) with risk recalculation every 5 years.
Intermediate Absolute Risk ( 5 % to below 10 % 5\%\text{ to below }10\% 5% to below 10% ) : Lifestyle modification combined with consideration of blood pressure-lowering and lipid-lowering pharmacotherapy if risk factors persist or reclassifying risk modifiers are present (e.g., elevated coronary artery calcium score, persistent socioeconomic disadvantage, family history of premature CVD).
High Absolute Risk ( ≥ 10 % \ge 10\% ≥ 10% ) : After discussing benefits and harms, prescribe blood-pressure-lowering and lipid-modifying treatment unless contraindicated or clinically inappropriate, alongside lifestyle support. Consider baseline pressure, adverse-effect risk and the patient’s preferences.
Clinically determined high risk
Established cardiovascular disease requires secondary prevention. In primary prevention, confirmed familial hypercholesterolaemia or moderate-to-severe CKD establishes high risk without calculation: sustained eGFR below 45 mL/min/1.73 m2 or persistent ACR above 25 mg/mmol in men or 35 in women. Diabetes alone after 60, BP above 180/110 or total cholesterol above 7.5 are older automatic categories and should not replace the current Australian algorithm. Treat severe hypertension and investigate very high lipids independently on their clinical merits.
For eligible patients, low five-year risk is below 5%, intermediate is 5 to below 10%, and high is at least 10%. Discuss lifestyle, preventive medication, benefits and adverse effects using absolute risk and preferences. Reclassification factors and secondary causes can modify the plan.
First-Line Pharmacotherapy and Antihypertensive Selection
Contemporary Australian guidelines recommend three core drug classes for initial therapy:
Angiotensin-Converting Enzyme (ACE) Inhibitors or Angiotensin Receptor Blockers (ARBs) :
Examples: Perindopril, ramipril, candesartan, telmisartan.
First-line for patients with type 2 diabetes, chronic kidney disease with albuminuria, heart failure, or history of myocardial infarction.
Adverse Effects: Dry cough occurs in 5 % to 10 % 5\%\text{ to }10\% 5% to 10% of patients on ACE inhibitors due to bradykinin accumulation (necessitating a switch to an ARB); angioedema; hyperkalaemia.
Dihydropyridine Calcium Channel Blockers (CCBs) :
Examples: Amlodipine, lercanidipine.
Potent vasodilators especially efficacious in older individuals and isolated systolic hypertension.
Adverse Effects: Dose-dependent peripheral ankle oedema (caused by precapillary arteriolar vasodilation rather than generalized fluid retention; does not respond to loop diuretics; combination with an ACEi/ARB reduces capillary hydrostatic pressure and resolves the oedema).
Thiazide-Like Diuretics :
Examples: Indapamide ( 1.25 to 2.5 mg 1.25\text{ to }2.5\text{ mg} 1.25 to 2.5 mg daily) or chlorthalidone .
Clinical Note : Thiazide-like diuretics are clinically superior to hydrochlorothiazide (HCTZ) due to longer half-lives, greater 24-hour ambulatory blood pressure reduction, and robust evidence of cardiovascular event reduction in randomized clinical trials.
Adverse Effects: Hypokalaemia, hyponatraemia, hyperuricaemia (may precipitate acute gout), and mild dyslipidaemia.
Treatment Strategies
Monotherapy : Suitable for mild hypertension (Grade 1) with low absolute cardiovascular risk.
Dual Combination Therapy : Recommended as first-line therapy for patients with baseline blood pressure ≥ 20 / 10 mmHg \ge 20/10\text{ mmHg} ≥ 20/10 mmHg above target, or those at high absolute CVD risk. Preferred combinations include an ACEi (or ARB) + CCB or an ACEi (or ARB) + Thiazide-like diuretic .
Beta-Blockers : No longer recommended as first-line monotherapy for uncomplicated primary hypertension because clinical trials show inferior protection against stroke compared to other classes. Beta-blockers are reserved for compelling cardiac indications (angina, HFrEF, post-myocardial infarction, rate control in atrial fibrillation).
Primary references (checked 7 October 2026): Australian CVD risk guideline .